NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akorn Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/akrx.
The investigation concerns whether Akorn and certain of its officers and/or directors have violated federal securities laws.
On January 9, 2019, Akorn revealed that it had received a warning letter from the U.S. Food and Drug Administration after an inspection of Akorn’s Decatur, Illinois manufacturing facility. This inspection exposed that contrary to what the Company relayed to investors, it had failed to comply with multiple federal regulations relating to drug manufacturing. Following this news, Akorn stock dropped $0.46 per share, or over 11.6%, to close at $3.48 on January 9, 2019.
If you are aware of any facts relating to this investigation, or purchased Akorn shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/akrx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com